Prophylactic use of granulocyte colony-stimulating factor in breast cancer chemotherapy in china: A retrospective observational study

Abstract: Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend risk-stratified prophylactic G-CSF therapy, which is indicated primarily for patients with a high risk of febrile neutropenia (FN >20%).Although G-CSF is widely used in clinical practice in China, it remains unclear whether this use aligns with guideline-recommended risk stratification, as few real-world studies have evaluated adherence. Objectives: This study aimed to evaluate the appropriateness of prophylactic G-CSF use in hospitalized breast cancer patients and identify the gap between clinical practice and current guidelines. Methods: In this single-center, retrospective observational study, we evaluated the prophylactic use of G-CSF according to FN risk category among breast cancer patients scheduled to receive myelosuppressive chemotherapy in hospitalized patients in China between January 2019 and December 2021. Results: A total of 4,181 chemotherapy cycles from 630 breast cancer patients were documented. The overall rate of prophylactic G-CSF use was 53.1%. Among these, 1,963 cycles (46.9%) involved inappropriate prophylactic use, including 1,836 cycles (43.9%) with underuse, 101 cycles (2.4%) with overuse and 26 cycles (0.6%) with non-standard use. Conclusion: This study reveals substantial inappropriate use of prophylactic G-CSF in Chinese breast cancer patients, primarily characterized by underuse in guideline-indicated scenarios.

Authors

Institutions

Publication Details

Journal
Pakistan Journal of Pharmaceutical Sciences
Published
2026-11-17
DOI
https://doi.org/10.36721/pjps/2026.40.16111.1
Primary Topic
Neutropenia and Cancer Infections
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Prophylactic use of granulocyte colony-stimulating factor in breast cancer chemotherapy in china: A retrospective observational study

Lilian Hu
Pakistan Journal of Pharmaceutical Sciences
Neutropenia and Cancer Infections
article

Prophylactic use of granulocyte colony-stimulating factor in breast cancer chemotherapy in china: A retrospective observational study

Lilian Hu
article en

Abstract

Abstract: Background: Febrile neutropenia (FN) is a serious complication of myelosuppressive chemotherapy. Clinical practice guidelines recommend risk-stratified prophylactic G-CSF therapy, which is indicated primarily for patients with a high risk of febrile neutropenia (FN >20%).Although G-CSF is widely used in clinical practice in China, it remains unclear whether this use aligns with guideline-recommended risk stratification, as few real-world studies have evaluated adherence. Objectives: This study aimed to evaluate the appropriateness of prophylactic G-CSF use in hospitalized breast cancer patients and identify the gap between clinical practice and current guidelines. Methods: In this single-center, retrospective observational study, we evaluated the prophylactic use of G-CSF according to FN risk category among breast cancer patients scheduled to receive myelosuppressive chemotherapy in hospitalized patients in China between January 2019 and December 2021. Results: A total of 4,181 chemotherapy cycles from 630 breast cancer patients were documented. The overall rate of prophylactic G-CSF use was 53.1%. Among these, 1,963 cycles (46.9%) involved inappropriate prophylactic use, including 1,836 cycles (43.9%) with underuse, 101 cycles (2.4%) with overuse and 26 cycles (0.6%) with non-standard use. Conclusion: This study reveals substantial inappropriate use of prophylactic G-CSF in Chinese breast cancer patients, primarily characterized by underuse in guideline-indicated scenarios.

Pakistan Journal of Pharmaceutical Sciences
Zunyi Medical University (CN), Affiliated Hospital of Zunyi Medical College (CN)
Good health and well-being
Neutropenia and Cancer Infections
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon